Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Oct. 22, 2013 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Osiris Therapeutics, Inc. ("Osiris" or the "Company") (NasdaqGM: OSIR). Such investors are advised to contact Peretz Bronstein or his Investor Relations coordinator Eitan Kimelman at email@example.com or 212-697-6484.
The investigation concerns whether Osiris and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On October 21, 2013, shares of Osiris fell $2.98 or 17.01% to close at $14.51 after the company said the Food and Drug Administration will treat its wound care product Grafix as a drug. The company said Grafix will remain on the market, but it will file a Biologics License Application to expand the drug's approval. According to the October 20, 2013 regulatory filing the Company will resolve concerns the FDA raised in an untitled letter dated September 26, 2013 and that Osiris and the FDA reached a resolution to these concerns on September 30, 2013.
If you are aware of any facts relating to this investigation, or purchased shares of Osiris, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
©2012 PR Newswire. All Rights Reserved.